Dan Kitwood/Getty Images/Cancer Research UK Shares of Nektar Therapeutics crashed 39% on Friday morning after the biopharmaceutical company divulged a quality-control issue with a key cancer therapy. The drug, which is called Bempegaldesleukin and intended to treat melanoma and other cancers, is still in the development and trial stages. Following the news, several Wall Street […]